Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
- Mar 5, 2024
- 2 min read
This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials.
WALTHAM, Mass., March 5, 2024 /PRNewswire/ -- Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, today announced receipt of a milestone payment following dosing of the first patient in a clinical trial conducted by AbbVie (NYSE: ABBV) to evaluate ABBV-303, a solid tumor targeting TriNKET®.
ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly's platform technology to enter the clinic, and the first AbbVie-licensed TriNKET® drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie's budigalimab (ABBV-181), in solid tumors.
"We are delighted that AbbVie has advanced ABBV-303 into the clinic," said Bill Haney, CEO and Dragonfly co-founder. "AbbVie is a global leader in advancing novel treatments for some of the most complex diseases and a terrific partner. We look forward to continued success and rapid progress with the AbbVie team to advance potential new treatment options for patients."
Additional information about the M24-122 Phase 1 trial, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT06158958).
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing novel therapies that harness the body's immune system to bring breakthrough treatments to patients. In addition to a set of advanced programs in the clinic, Dragonfly has a deep pipeline of wholly owned preclinical candidates discovered using its proprietary platforms that are progressing toward the clinic, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit:www.dragonflytx.comhttps://www.linkedin.com/company/dragonfly-therapeutics-inc./https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
Seeing Dragonfly receive their milestone bonus makes me genuinely happy for them; it feels just like safely navigating a treacherous slope. It reminds me of driving the egg-carrying vehicle in eggy car over the trickiest, most undulating hills—as long as you stay on the right path and maintain a steady rhythm, you’re bound to reach the finish line successfully!
51 Game was quick and easy. The game offers great entertainment with interesting features and levels. I’ve been playing daily and it keeps getting more engaging every time
Trump threatens BG 678 new tariffs on European allies over Greenland until deal reached, as thousands protest
Reaching clinical trial milestones like this is such huge news for cancer research! For instance, when taking on custom vehicle refinishing or body restoration, using a high-quality Automotive Basecoat is essential for achieving exact color matching and smooth, seamless coverage. Whether in medical research or hands-on craftsmanship, attention to detail and setting solid foundations is what leads to success. Thanks for sharing this exciting progress update!
Trump threatens in999 new tariffs on European allies over Greenland until deal reached, as thousands protest